ATE501127T1 - Neue cysteinproteasehemmer und ihre therapeutische anwendung - Google Patents

Neue cysteinproteasehemmer und ihre therapeutische anwendung

Info

Publication number
ATE501127T1
ATE501127T1 AT06808884T AT06808884T ATE501127T1 AT E501127 T1 ATE501127 T1 AT E501127T1 AT 06808884 T AT06808884 T AT 06808884T AT 06808884 T AT06808884 T AT 06808884T AT E501127 T1 ATE501127 T1 AT E501127T1
Authority
AT
Austria
Prior art keywords
therapeutic use
new
protease inhibitors
cystein protease
cystein
Prior art date
Application number
AT06808884T
Other languages
English (en)
Inventor
Philippe Guedat
Guillaume Boissy
Catherine Borg-Capra
Frederic Colland
Laurent Daviet
Etienne Formstecher
Xavier Jacq
Jean-Christophe Rain
Remi Delansorne
Stefania Vallese
Matteo Colombo
Original Assignee
Hybrigenics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/197,525 external-priority patent/US20070032499A1/en
Priority claimed from EP05291683A external-priority patent/EP1749822B1/de
Application filed by Hybrigenics Sa filed Critical Hybrigenics Sa
Application granted granted Critical
Publication of ATE501127T1 publication Critical patent/ATE501127T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
AT06808884T 2005-08-05 2006-07-26 Neue cysteinproteasehemmer und ihre therapeutische anwendung ATE501127T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/197,525 US20070032499A1 (en) 2005-08-05 2005-08-05 Novel cysteine protease inhibitors and their therapeutic applications
EP05291683A EP1749822B1 (de) 2005-08-05 2005-08-05 Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
PCT/IB2006/002637 WO2007017758A2 (en) 2005-08-05 2006-07-26 Novel cysteine protease inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
ATE501127T1 true ATE501127T1 (de) 2011-03-15

Family

ID=37507720

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06808884T ATE501127T1 (de) 2005-08-05 2006-07-26 Neue cysteinproteasehemmer und ihre therapeutische anwendung

Country Status (16)

Country Link
US (1) US8648076B2 (de)
EP (1) EP1912954B1 (de)
JP (2) JP5523703B2 (de)
AT (1) ATE501127T1 (de)
AU (1) AU2006277678B2 (de)
CA (1) CA2617725C (de)
DE (1) DE602006020585D1 (de)
DK (1) DK1912954T3 (de)
ES (1) ES2363743T3 (de)
IL (1) IL189286A (de)
NO (1) NO20080661L (de)
NZ (1) NZ565670A (de)
PL (1) PL1912954T3 (de)
RU (1) RU2424234C2 (de)
UA (1) UA96269C2 (de)
WO (1) WO2007017758A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
AU2007315885B2 (en) * 2006-10-30 2013-01-31 Hybrigenics Sa Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
EP2824113B1 (de) 2013-07-09 2017-05-03 Samsung Electronics Co., Ltd Biomarker zur auswahl einer person zur anwendung eines anti-c-met-antikörpers
WO2016039750A1 (en) 2014-09-11 2016-03-17 Halliburton Energy Services, Inc. Cyanamide-based carbon dioxide and/or hydrogen sulfide scavengers and methods of use in subterranean operations
WO2017082246A1 (ja) * 2015-11-10 2017-05-18 国立大学法人九州大学 ジシアノピラジン化合物、発光材料、それを用いた発光素子、および２，５－ジシアノ－３，６－ジハロゲノピラジンの製造方法
US20230087388A1 (en) * 2020-02-28 2023-03-23 Immunologik Gmbh Inhibitors of human deubiquitinases for the treatment of coronaviral infections

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3219339B2 (ja) * 1993-06-15 2001-10-15 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH0798508A (ja) * 1993-09-28 1995-04-11 Ricoh Co Ltd 単層型電子写真感光体
JPH07175235A (ja) 1993-12-20 1995-07-14 Ricoh Co Ltd 単層型電子写真用感光体
JP3255525B2 (ja) 1993-12-23 2002-02-12 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH07199486A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07199487A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07281460A (ja) 1994-04-14 1995-10-27 Ricoh Co Ltd 潜像転写用電子写真感光体
HUP0000475A3 (en) * 1996-12-11 2002-11-28 Basf Ag Ketobenzamides as calpain inhibitors
JP2000122316A (ja) 1998-10-19 2000-04-28 Ricoh Co Ltd 電子写真感光体
JP2000128885A (ja) 1998-10-19 2000-05-09 Ricoh Co Ltd テトラピラジノポルフィラジン化合物及びその製造方法
JP2001028885A (ja) 1999-07-12 2001-01-30 Sanyo Electric Co Ltd 電源装置
US20040109690A1 (en) * 2001-01-30 2004-06-10 Yoshinobu Maeda Optical control method and device
US20040198716A1 (en) * 2001-02-05 2004-10-07 Dorit Arad Cysteine protease inhimbitors
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
HUP0402344A2 (hu) 2001-12-04 2005-02-28 F. Hoffmann-La Roche Ag Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU2002357515A1 (en) 2001-12-26 2003-07-15 Nippon Soda Co., Ltd. Electron-accepting compounds capable of forming self-assembled monolayers
AU2003266052B2 (en) 2002-09-04 2009-04-23 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications

Also Published As

Publication number Publication date
IL189286A (en) 2013-08-29
JP2009503052A (ja) 2009-01-29
CA2617725C (en) 2012-04-03
EP1912954B1 (de) 2011-03-09
JP2013166798A (ja) 2013-08-29
JP5523703B2 (ja) 2014-06-18
IL189286A0 (en) 2008-06-05
AU2006277678B2 (en) 2012-04-19
DK1912954T3 (da) 2011-05-23
ES2363743T3 (es) 2011-08-12
WO2007017758A3 (en) 2007-04-19
US8648076B2 (en) 2014-02-11
UA96269C2 (uk) 2011-10-25
NO20080661L (no) 2008-03-04
RU2008108501A (ru) 2009-09-10
RU2424234C2 (ru) 2011-07-20
WO2007017758A2 (en) 2007-02-15
PL1912954T3 (pl) 2011-09-30
EP1912954A2 (de) 2008-04-23
DE602006020585D1 (de) 2011-04-21
US20090215786A1 (en) 2009-08-27
NZ565670A (en) 2010-01-29
AU2006277678A1 (en) 2007-02-15
CA2617725A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
EA201070247A1 (ru) Ингибиторы протеасом
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA201790678A1 (ru) Бициклические гетероарильные соединения
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA200801199A1 (ru) Ингибиторы киназы
TW200745122A (en) New compounds I
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
TW200745039A (en) Isotopically substituted pantoprazole
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
EA201170344A1 (ru) Азаиндольные ингибиторы iap
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
ATE501127T1 (de) Neue cysteinproteasehemmer und ihre therapeutische anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1912954

Country of ref document: EP